Drugs / AVE9633
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00543972 | Sep 2007 → Aug 2008 | myeloid leukemia | Sanofi | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2007-12-09 | AbbVie | Results ImmunoGen, Inc. Announces Encouraging Clinical Findings Reported at ASH Annual Meeting for TAP Compound AVE9633 abbvie.com ↗
AVE9633 demonstrated evidence of biological activity in multiple patients with relapsed/refractory acute myeloid leukemia (AML) and was found to be generally well tolerated. |
| 2006-04-01 | AbbVie | Results ImmunoGen, Inc. Announces Eight Posters to be Presented at AACR on its TAP Technology and on Compounds in Development abbvie.com ↗
Data on the activity of the TAP compound AVE9633, now in clinical development by the sanofi-aventis Group, against human acute myeloid leukemia cells isolated from patients (abstract #5558); |
| 2005-04-19 | AbbVie | Results ImmunoGen, Inc. Announces Data Reported at AACR on AVE9633 Anticancer Compound abbvie.com ↗
In vivo, AVE9633 was able to eradicate tumors consisting of human leukemia cells in xenograft models, and achieved complete responses and cures at doses that caused little or no toxicity. |
All press releases naming this drug 3 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AVE9633 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00543972 ↗ |
| Known as | HUMY9-6 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109266 ↗ |
| Route | Intravenous | “Intravenous Infusion” NCT00543972 ↗ |
| Target | CD33 | “Myeloid cell surface antigen CD33 binding agent” CHEMBL2109266 ↗ |